Pharming Group NV
AEX:PHARM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.688
1.713
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Pharming Group NV
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Revenue Growth: Pharming’s Q3 2025 revenues rose 30% year-on-year to $97.3 million, with both RUCONEST and Joenja posting strong double-digit growth.
Profit Surge: Operating profit soared to $16 million, nearly four times last year's figure for the same quarter.
Guidance Raised: Full-year 2025 revenue guidance was increased to $365–375 million from the previous $335–350 million, reflecting strong momentum.
RUCONEST Momentum: RUCONEST revenue climbed 29% to $82 million, showing resilience despite a new oral competitor and continued increases in patients and prescribers.
Joenja Expansion: Joenja revenues jumped 35% to $15.1 million, as patient numbers grew and U.S. and international launches progressed; pediatric approval is expected in early 2026.
Margins Up: Gross margin improved to 93% from 91% last year, aided by sales mix and operational efficiency.
Pipeline Advances: Late-stage programs remain on track; notable is the upcoming pediatric indication for Joenja and promising developments for KL1333.
Cost Discipline: Significant G&A headcount reduction and disciplined capital deployment were highlighted as key measures to support growth.
